XGene Pharmaceutical

Breakthrough Innovation In Non-Opioid Pain Treatment

About this Event

The global pain market exceeds $87B with opioids accounting for $22B despite their well-known risks. Xgene Pharmaceutical, a clinical-stage biotech, is developing safer, more effective non-opioid alternatives for both acute and chronic pain.

Xgene’s proprietary multimodal conjugate technology combines two therapeutic molecules (Naproxin and pregabalin) into a single, dual-acting medication that reduces inflammatory cytokines and inhibits pain signal transmission with minimal side effects. The linker is a patented conjugate. Xgene recently completed Phase 2 trials for post-surgical and chronic pain, with 43% of patients requiring no rescue medication, and 74% avoiding opioids entirely.

Please register to watch our Fireside Chat with Feng Xu Ph.D. Chief Operating Officer, Chief Scientific Officer, & Founder and Iwona Beczkowska Ph.D. Head of Business Development for XGene. With a robust pipeline of innovative, non-opioid therapeutics, Xgene is positioned to transform pain management for millions worldwide.

Video On Demand

– Recorded

March 5

SHARE THIS EVENT

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.